Management ChangeMay 8, 2026, 07:16 AM
iBio Appoints Elizabeth Stoner to Board of Directors
AI Summary
iBio, Inc. announced the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors as an independent member and to the Compensation Committee. Dr. Stoner replaces Eef Schimmelpennink, who stepped down from the Board. Dr. Stoner brings over 35 years of research and development leadership experience, including roles at MPM BioImpact, Semma Therapeutics, Rhythm Pharmaceuticals, and Merck Research Laboratories, which will be valuable as iBio advances its clinical programs.
Key Highlights
- iBio appointed Elizabeth Stoner, M.D., M.S. as an independent member to its Board of Directors.
- Dr. Stoner will also serve as a member of the Compensation Committee.
- Eef Schimmelpennink stepped down from the Board of Directors.
- Dr. Stoner brings over 35 years of research and development leadership experience.
- She is currently an Entrepreneur Partner at MPM BioImpact, a biotechnology investment firm.
- Her experience includes senior leadership roles at Semma Therapeutics, Rhythm Pharmaceuticals, and Merck Research Laboratories.
- Dr. Stoner's expertise spans endocrine, metabolic, and cardiovascular programs, with global regulatory and clinical execution.
Price Impact
More from IBIO